NF-κB

Overview

Nuclear Factor kappa-B (NF-κB) is a transcription factor and central signaling pathway that regulates the expression of genes involved in inflammation, immunity, cell proliferation, and apoptosis. In its inactive state, NF-κB is sequestered in the cytoplasm bound to inhibitory proteins; upon activation via multiple upstream signals, it translocates to the nucleus to initiate transcriptional programs. NF-κB activation is triggered by diverse stimuli including cytokines (such as TNF-α), pathogen-associated molecular patterns detected by toll-like receptors (toll like receptor 4 (TLR4)), and cellular stress signals. The pathway is fundamental to innate and adaptive immune responses but becomes pathologically dysregulated in chronic inflammatory diseases, cancer, aging, and degenerative conditions.

Because NF-κB controls pro-inflammatory gene expression and cell survival, its inhibition has emerged as a major therapeutic strategy across multiple disease indications. The challenge lies in targeting NF-κB selectively to suppress pathological inflammation while preserving protective immune functions—a balance reflected in recent research efforts using natural compounds, synthetic inhibitors, and combination therapies.

Recent Publications Summary

Recent studies continued to position NF-κB as a central inflammatory signaling node across diverse disease models, with multiple interventions reported to suppress its activation alongside improvements in tissue injury or clinical phenotypes. In rheumatoid arthritis, Lactobacillus casei was shown to reshape gut microbiota, increase butyrate production, modulate HDAC expression, and inhibit NF-κB pathway activation, contributing to reduced synovial inflammation and joint damage 42482368Jul. Similarly, Shaoyao Gancao Decoction was reported to ameliorate rheumatoid arthritis through inhibition of TNF-α/NF-κB signaling 41866004Mar, while Scutellaria baicalensis improved polycystic ovary syndrome by modulating gut microbiota composition and inhibiting the LPS/TLR4/NF-κB pathway 42294648Jun.

NF-κB was also implicated in injury and stress-response settings. Nanocurcumin attenuated desert dry-heat-induced exertional heat stroke brain injury in rats by suppressing the TLR4/MyD88/NF-κB axis 42396648Jul, and astaxanthin reduced ischemic stroke-associated brain damage and apoptosis while lowering TLR4, MyD88, NF-κB, and inflammatory markers 42050264Apr. In spinal cord injury, betulinic acid was reported to promote motor recovery and reduce inflammatory cytokines through the Myc/NF-κB signaling pathway 42477269Jul. In radiobiology, both flattening filter and flattening filter-free irradiation increased inflammatory cytokine expression and NF-κB p65 activation in heart and lung tissues, with stronger responses after flattening filter-free delivery 42411639Jul.

Additional studies linked NF-κB modulation to metabolic, hepatic, and systemic inflammatory disease. Babaodan was reported to ameliorate metabolic dysfunction-associated steatotic liver disease through co-modulation of FXR, NF-κB, and SLC22A7, with hepatocytes identified as a key site of bile acid disruption and NF-κB-driven inflammation 42472598Jul. salvianolic acid B was investigated as a TNFR1-targeting agent that could simultaneously inhibit NF-κB, necroptosis, and epithelial barrier damage in sepsis-induced acute lung and intestinal injury 42176509May. In cancer-related and biotechnology contexts, gold ceria nanohybrids suppressed nuclear NF-κB-p65 expression in breast cancer cells 42240071Jun, and CBL0137 enhanced CRISPR base and prime editing efficiency partly through NF-κB inhibition 41692169Feb. Across these reports, NF-κB repeatedly emerged as a mechanistic hub connecting inflammation, apoptosis, barrier dysfunction, and tissue remodeling.

What Changes, What Holds

1. NF-κB remains a broadly validated inflammatory target, but these studies mainly extend its disease map rather than alter its core biology
REINFORCES The new work strengthens the baseline view of NF-κB as a central node in inflammatory disease by showing repeated benefit from pathway suppression across autoimmune and endocrine contexts. It does not displace the established account of NF-κB as a mediator of inflammation, immunity, and tissue injury; instead, it adds more examples of upstream modulation through microbiota-linked and TNF/TLR4-linked mechanisms 42482368Jul41866004Mar.

2. NF-κB inhibition continues to track with protection in acute injury models, but the evidence stays preclinical and mechanistically convergent
REINFORCES These findings fit the baseline’s description of NF-κB as a stress-responsive driver of inflammatory damage and apoptosis. The new studies do not introduce a new role or contradict the established pathway; they reinforce the idea that blocking TLR4/MyD88/NF-κB or related signaling can reduce tissue injury in brain, spinal cord, and radiation-exposed organs, while leaving open how well these effects translate beyond animal models 42396648Jul42050264Apr.

3. NF-κB is increasingly framed as a hub linking inflammation to metabolic and barrier injury, but that expands rather than overturns the baseline
REINFORCES The recent reports sharpen the baseline by placing NF-κB at the intersection of liver metabolism, sepsis-related barrier failure, and cancer-cell signaling. That broadens the pathway’s disease reach without challenging its established inflammatory and survival functions. The main unresolved issue is not whether NF-κB matters, but how selectively it can be modulated when it sits inside overlapping FXR, TNFR1, and epigenetic networks 42472598Jul42176509May.